Atai Beckley Inc Stock Price, News & Analysis

AtaiBeckley (NASDAQ: ATAI) announced completion of the strategic combination between atai Life Sciences and Beckley Psytech on Nov 5, 2025, creating a clinical‑stage company focused on psychedelic‑based neuroplastogens.

Key facts: BPL-003 is Phase 3‑ready with FDA Breakthrough Therapy designation and Phase 3 initiation expected Q2 2026; VLS-01 topline data expected H2 2026; EMP-01 topline data expected Q1 2026. Management and board roles were established and the company expects cash and liquid assets to fund operations into 2029. The deal issues ~105 million new shares (~28% of combined company) and a Delaware redomiciliation is expected around year‑end.

atai Life Sciences (NASDAQ: ATAI) closed a public offering on October 20, 2025, issuing 27,283,750 common shares (including full exercise of a 3,558,750-share underwriter option) at $5.48 per share.

The offering generated approximately $149.5 million in aggregate gross proceeds before fees. atai said it will use net proceeds together with existing cash and liquid assets to fund its pipeline, including the planned Phase 3 program for BPL-003 through first top-line readout, completion of the Phase 2 VLS-01 trial and the Phase 2a EMP-01 study, plus working capital. Based on this use, atai estimates cash will fund operations into 2029.

atai Life Sciences (NASDAQ: ATAI) priced an underwritten public offering of 23,725,000 common shares at $5.48 per share and granted underwriters a 30-day option to buy up to an additional 3,558,750 shares. Gross proceeds are expected to be approximately $130 million before fees. The company said it will use net proceeds, together with existing cash and short-term investments, to advance clinical development of product candidates and for working capital and general corporate purposes. The offering is expected to close on October 20, 2025, subject to customary closing conditions, with Jefferies as lead bookrunner.

atai Life Sciences (NASDAQ: ATAI) announced on October 16, 2025 the commencement of a proposed registered underwritten offering of its common shares.

The company said it expects to grant underwriters a 30-day option to purchase additional common shares and that all shares will be sold by atai. The offering is subject to market and other conditions and may not be completed.

atai intends to use net proceeds, together with existing cash and short-term investments, to advance clinical development, and for working capital and general corporate purposes. Jefferies is lead bookrunner.

atai Life Sciences (NASDAQ: ATAI) and Beckley Psytech announced that the U.S. FDA has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adult patients with treatment-resistant depression (TRD).

Designation follows positive Phase 2b topline results where a single 8 mg or 12 mg dose produced clinically meaningful, statistically significant symptom reductions within 24 hours with effects sustained through an 8-week trial; most patients were ready for discharge by 90 minutes post-dose. The companies state Phase 3 trials are expected to begin in Q2 2026, subject to FDA alignment.

atai Life Sciences (NASDAQ: ATAI) and Beckley Psytech announced positive Phase 2a data for their treatment-resistant depression (TRD) drug BPL-003. The study evaluated a two-dose regimen (8mg followed by 12mg after two weeks) in 13 TRD patients.

Key findings showed rapid and durable efficacy with mean MADRS score reductions of 13.3 points at Day 2 and further improvement to 19.0 points after the second dose. Remission rates increased from 25% after the first dose to 50% at Week 8. The treatment demonstrated strong tolerability with only mild to moderate adverse events.

Following these positive results and pending FDA feedback, the companies plan to initiate Phase 3 clinical trials in H1 2026.

atai Life Sciences (NASDAQ: ATAI) has secured a significant $11.4 million UG3/UH3 grant from the National Institute on Drug Abuse (NIDA) to develop novel treatments for opioid use disorder (OUD). The grant will fund the development of non-hallucinogenic 5-HT2A/2C receptor agonists, marking the first external validation of atai's AI-driven polypharmacology drug discovery approach.

The funding will support lead optimization, translational proof-of-concept studies, and preparations for an IND application. The company aims to develop compounds that maintain therapeutic efficacy while minimizing hallucinogenic effects and avoiding cardiac risks. This initiative addresses a critical global health crisis, with OUD affecting 16 million people worldwide and causing over 120,000 annual deaths, with associated costs exceeding $750 billion annually.

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, has announced its participation in three major investor conferences this September.

The company will participate in fireside chat sessions at the Cantor Global Healthcare Conference on September 5th, the H.C. Wainwright Global Investment Conference on September 8th, and the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17th. All presentations will be available via webcast on the company's investor relations website, with replays accessible after the events.

atai Life Sciences (NASDAQ: ATAI) reported Q2 2025 financial results and corporate updates, highlighting its planned strategic combination with Beckley Psytech. The company announced positive Phase 2b results for BPL-003 (intranasal mebufotenin benzoate) in treatment-resistant depression, meeting primary and secondary endpoints with a single dose showing effects for up to 8 weeks.

Financial position shows $95.9 million in cash and equivalents as of June 30, 2025, with funding expected into second half of 2027. Q2 2025 saw R&D expenses of $11.1 million (down from $12.6M YoY) and net loss of $27.7 million (improved from $57.3M YoY). The company raised nearly $140 million in 2025 through fundraising efforts.

Pipeline updates include delayed VLS-01 Phase 2 trial data now expected in H2 2026, ongoing EMP-01 Phase 2 study for social anxiety disorder, and development of novel 5-HT2A receptor agonists.